NDC-11 (Package) (Descending) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
60505-3877-03 | 60505-3877 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov. 25, 2015 | Jan. 31, 2021 | No Longer Used |
60505-3817-03 | 60505-3817 | Dasatinib | Dasatinib | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 3, 2024 | In Use | |
60505-3816-03 | 60505-3816 | Dasatinib | Dasatinib | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 3, 2024 | In Use | |
60505-3631-03 | 60505-3631 | Dasatinib | Dasatinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 3, 2024 | In Use | |
60505-3630-06 | 60505-3630 | Dasatinib | Dasatinib | 70.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 3, 2024 | In Use | |
60505-3629-06 | 60505-3629 | Dasatinib | Dasatinib | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 3, 2024 | In Use | |
60505-3628-06 | 60505-3628 | Dasatinib | Dasatinib | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sept. 3, 2024 | In Use | |
60505-3255-08 | 60505-3255 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | May 31, 2012 | May 31, 2019 | No Longer Used | |
60505-3255-03 | 60505-3255 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | May 31, 2012 | Dec. 31, 2021 | No Longer Used | |
60505-3255-01 | 60505-3255 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | May 31, 2012 | May 31, 2019 | No Longer Used | |
60505-3036-07 | 60505-3036 | Tamoxifen Citrate | Tamoxifen Citrate | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Nov. 30, 2012 | Dec. 1, 2012 | No Longer Used | ||
60505-3036-03 | 60505-3036 | Tamoxifen Citrate | Tamoxifen Citrate | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Nov. 30, 2012 | Dec. 1, 2012 | No Longer Used | ||
60505-3036-01 | 60505-3036 | Tamoxifen Citrate | Tamoxifen Citrate | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Nov. 30, 2012 | Dec. 1, 2012 | No Longer Used | ||
60505-3035-07 | 60505-3035 | Tamoxifen Citrate | Tamoxifen Citrate | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Nov. 30, 2012 | Dec. 1, 2012 | No Longer Used | ||
60505-3035-06 | 60505-3035 | Tamoxifen Citrate | Tamoxifen Citrate | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Nov. 30, 2012 | Dec. 1, 2012 | No Longer Used | ||
60505-3035-05 | 60505-3035 | Tamoxifen Citrate | Tamoxifen Citrate | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Nov. 30, 2012 | Dec. 1, 2012 | No Longer Used | ||
60505-3035-03 | 60505-3035 | Tamoxifen Citrate | Tamoxifen Citrate | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Nov. 30, 2012 | Dec. 1, 2012 | No Longer Used | ||
60505-2985-03 | 60505-2985 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | May 31, 2012 | March 1, 2021 | No Longer Used | |
60505-2901-09 | 60505-2901 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug. 5, 2016 | In Use | |
60505-2901-05 | 60505-2901 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug. 5, 2016 | In Use | |
60505-2901-03 | 60505-2901 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug. 5, 2016 | In Use | |
60505-2901-01 | 60505-2901 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug. 5, 2016 | In Use | |
60505-2901-00 | 60505-2901 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug. 5, 2016 | In Use | |
60505-2900-09 | 60505-2900 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug. 5, 2016 | In Use | |
60505-2900-08 | 60505-2900 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug. 5, 2016 | In Use |
Found 10,000 results in 7 milliseconds — Export these results